"Based on its current operating and development plans, Jounce continues to expect gross cash burn on operating expenses and capital expenditures for the full year 2020 to be approximately $80.0 million to $95.0 million.
Given the strength of its balance sheet, Jounce expects its existing cash, cash equivalents and investments to be sufficient to enable the funding of its operating expenses and capital expenditure requirements through the end of 2021."
Die EMERGE-Phase2 Studie von vopratelimab in Kombination mit ipilimumab wird nicht fortgeführt
"We are disappointed that an early look at the EMERGE data indicates that we will not meet our pre-specified interim criteria for continued enrollment,? said Beth Trehu, M.D., Chief Medical Officer at Jounce Therapeutics.